Optimal Dosage of Carboplatin (CP) in Advanced Epithelial Ovarian Cancer (AEOC)

Abstract

The evaluation of efficacy and toxicity of combined carboplatin (CBP) in two different doses with fixed dose of cyclophosphamide (CTX) for treatment of advanced ovarian epithelial cancer was performed. The patients were treated by these combination after randomisation every 3 weeks for 8 cycles. Arm A (CBP 300 mg/m2 + CTX 500 mg/m2) achieved the over all response rate of 70.0% and clinical complete response rate of 50.0%, arm B (CBP 400 mg/m2 + CTX 500 mg/m2) had over all response and complete response rate of 80.0% and 75.0% respectively (p = 0.1). The pathological complete response showed in both arms 77.77% and 76.92% (P = 0.39), with recurrence 28.57% and 20.0% (P = 0.39). The survival rate were constructed by Kaplan and Meier's method, with 3 years survival rate of 40.0% and 55.0% respectively (P = 0.14). The me dian survival was 25.0 months in arm A, and 35.5 months in arm B (P = 0.29). The haematologic toxicity grade 4 was noted in few patients of both arms. Nausea and vomiting were minimal after prophylactic antiemetic. No hepatotoxicity, nephrotoxicity and neurotoxicity were noted. (Thai J Obstet Gynaecol 1995; 7:61-68.)